IntegriChain, a Philadelphia-based provider of revenue optimization technology and consulting for the pharmaceutical industry, has appointed Chris Hare as Chief Revenue Officer, the company announced on October 27, 2026. Hare brings more than two decades of experience building and scaling revenue organizations across healthcare and healthcare SaaS. He’ll lead IntegriChain’s commercial strategy as the company marks its 20th anniversary and prepares for continued growth in 2027.
Josh Halpern, CEO of IntegriChain, said Hare understands the company’s customers from his years in pharmaceutical sales and has repeatedly built predictable, scalable growth engines at healthcare technology companies. “He’s the leader we trust to guide our commercial organization,” Halpern said.
Hare said he’s thrilled to join, and that he was drawn by the strength of the business, the momentum of the team, and above all the people and culture behind it.
About Chris Hare
Hare most recently served as Chief Growth and Revenue Officer at Intelerad, where he led the growth team to annual double-digit growth. That growth contributed to Intelerad’s acquisition by GE HealthCare in April 2026 for $2.3 billion. Before Intelerad, he was Executive Vice President of Sales at Net Health, where he led sales for a specialty healthcare SaaS portfolio spanning EMR, revenue cycle management and predictive analytics, and launched multiple new product lines. He was previously Chief Growth Officer at Rhinogram, a digital healthcare communication company.
For more than a decade, Hare also ran CKH Executive Consulting. As founder and operating partner, he advised angel, venture and private equity-backed healthcare and digital health companies on growth strategy and led their sales, marketing, business development and customer success teams. Earlier, as Director of Urology Sales at Miraca Life Sciences, an anatomic pathology services company, he built a new urology division from the ground up. He began his career at Salix Pharmaceuticals, where he was a top-producing sales representative and leader in the commercial business.
Hare holds a B.A. from Trevecca Nazarene University.
About IntegriChain
IntegriChain offers a data-driven commercialization platform for biopharma, connecting the commercial, financial and operational dimensions of drug access and profitability. Its ICyte® Platform integrates technology, data, consulting and managed services to unify critical workflows, helping manufacturers optimize patient access and net revenue, reduce leakage and strengthen compliance. IntegriChain is backed by Nordic Capital and headquartered in Philadelphia, with a location in Pune, India.
